Lin Hisao's questions to Zai Lab Ltd (ZLAB) leadership • Q1 2024
Question
Lin Hisao of Goldman Sachs asked about the filing plans for adagrasib following recent trial data and the expected timeline for an MAA submission for Optune in second-line NSCLC in China.
Answer
Dr. Rafael Amado, President and Head of Global Oncology R&D, explained that for adagrasib, they are awaiting further data evaluation by partner BMS before finalizing plans. For Optune, he confirmed they expect to submit the MAA in China this year based on the LUNAR study results, without necessarily waiting for FDA approval.